CA2585876A1 - Immunosorbent tests for assessing paroxysmal cerebral discharges - Google Patents
Immunosorbent tests for assessing paroxysmal cerebral discharges Download PDFInfo
- Publication number
- CA2585876A1 CA2585876A1 CA002585876A CA2585876A CA2585876A1 CA 2585876 A1 CA2585876 A1 CA 2585876A1 CA 002585876 A CA002585876 A CA 002585876A CA 2585876 A CA2585876 A CA 2585876A CA 2585876 A1 CA2585876 A1 CA 2585876A1
- Authority
- CA
- Canada
- Prior art keywords
- glur1
- epilepsy
- fragment
- antibodies
- paroxysmal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001314 paroxysmal effect Effects 0.000 title claims abstract description 47
- 230000002490 cerebral effect Effects 0.000 title abstract description 17
- 239000003547 immunosorbent Substances 0.000 title abstract description 12
- 238000012360 testing method Methods 0.000 title description 35
- 206010015037 epilepsy Diseases 0.000 claims abstract description 136
- 206010010904 Convulsion Diseases 0.000 claims abstract description 107
- 238000000034 method Methods 0.000 claims abstract description 88
- 239000012634 fragment Substances 0.000 claims abstract description 62
- 241000282414 Homo sapiens Species 0.000 claims abstract description 17
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 16
- 239000012472 biological sample Substances 0.000 claims abstract description 12
- 230000002082 anti-convulsion Effects 0.000 claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 89
- 239000004816 latex Substances 0.000 claims description 34
- 229920000126 latex Polymers 0.000 claims description 34
- 239000013060 biological fluid Substances 0.000 claims description 24
- 230000004520 agglutination Effects 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 239000001961 anticonvulsive agent Substances 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 14
- 238000002965 ELISA Methods 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 238000012421 spiking Methods 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 210000002381 plasma Anatomy 0.000 claims description 12
- 230000001773 anti-convulsant effect Effects 0.000 claims description 10
- 229960003965 antiepileptics Drugs 0.000 claims description 10
- 206010042772 syncope Diseases 0.000 claims description 10
- 208000006011 Stroke Diseases 0.000 claims description 9
- 102000018899 Glutamate Receptors Human genes 0.000 claims description 8
- 108010027915 Glutamate Receptors Proteins 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 7
- 230000002163 immunogen Effects 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 206010013654 Drug abuse Diseases 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 208000003443 Unconsciousness Diseases 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims description 3
- 210000005013 brain tissue Anatomy 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000037029 cross reaction Effects 0.000 claims description 3
- 230000001107 psychogenic effect Effects 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002265 sensory receptor cell Anatomy 0.000 claims description 3
- 230000004523 agglutinating effect Effects 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 238000002875 fluorescence polarization Methods 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 238000012123 point-of-care testing Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000004556 brain Anatomy 0.000 abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 22
- 208000012902 Nervous system disease Diseases 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 7
- 208000015114 central nervous system disease Diseases 0.000 abstract description 4
- 238000003556 assay Methods 0.000 description 24
- 230000035945 sensitivity Effects 0.000 description 18
- 238000003018 immunoassay Methods 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 230000001037 epileptic effect Effects 0.000 description 13
- 208000011580 syndromic disease Diseases 0.000 description 13
- 239000000090 biomarker Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 108090000078 AMPA Receptors Proteins 0.000 description 10
- 102000003678 AMPA Receptors Human genes 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 208000025966 Neurological disease Diseases 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- -1 kits Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 6
- 208000002877 Epileptic Syndromes Diseases 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- 201000011252 Phenylketonuria Diseases 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000001057 ionotropic effect Effects 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 206010027202 Meningitis bacterial Diseases 0.000 description 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
- 208000037158 Partial Epilepsies Diseases 0.000 description 3
- 206010061334 Partial seizures Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000007818 agglutination assay Methods 0.000 description 3
- 201000009904 bacterial meningitis Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006931 brain damage Effects 0.000 description 3
- 231100000874 brain damage Toxicity 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 201000001913 Childhood absence epilepsy Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010058895 Psychogenic seizure Diseases 0.000 description 2
- 206010042464 Suicide attempt Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 208000003554 absence epilepsy Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 101710135378 pH 6 antigen Proteins 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical class NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010005456 AMPA 4 glutamate receptor ionotropic Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 101001074427 Bacillus subtilis (strain 168) Polyketide synthase PksJ Proteins 0.000 description 1
- 101001074418 Bacillus subtilis (strain 168) Polyketide synthase PksL Proteins 0.000 description 1
- 206010070530 Benign rolandic epilepsy Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010012177 Deja vu Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101000803786 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Conidial yellow pigment biosynthesis polyketide synthase Proteins 0.000 description 1
- 101000701349 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Putative sterigmatocystin biosynthesis polyketide synthase Proteins 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100030668 Glutamate receptor 4 Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000004974 Rolandic Epilepsy Diseases 0.000 description 1
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 1
- 101000730455 Serratia sp. (strain ATCC 39006) Beta-ketoacyl synthase PigJ Proteins 0.000 description 1
- 101000691656 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA1, modules 1 and 2 Proteins 0.000 description 1
- 101000691655 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA2, modules 3 and 4 Proteins 0.000 description 1
- 101000691658 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA3, module 5 Proteins 0.000 description 1
- 101001125873 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA4, module 6 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000008916 benign epilepsy with centrotemporal spikes Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 208000033205 childhood epilepsy with centrotemporal spikes Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001787 epileptiform Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000021057 glutamate binding proteins Human genes 0.000 description 1
- 108091011212 glutamate binding proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011317 proteomic test Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 208000028325 tonic-clonic seizure Diseases 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51767103P | 2003-11-06 | 2003-11-06 | |
| US60/517,671 | 2003-11-06 | ||
| PCT/US2004/037088 WO2005046442A2 (en) | 2003-11-06 | 2004-11-08 | Immunosorbent tests for assessing paroxysmal cerebral discharges |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2585876A1 true CA2585876A1 (en) | 2005-05-26 |
Family
ID=34590180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002585876A Abandoned CA2585876A1 (en) | 2003-11-06 | 2004-11-08 | Immunosorbent tests for assessing paroxysmal cerebral discharges |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7820398B2 (enExample) |
| EP (1) | EP1689288B1 (enExample) |
| JP (1) | JP4838140B2 (enExample) |
| CN (1) | CN1954211A (enExample) |
| AT (1) | ATE465412T1 (enExample) |
| AU (1) | AU2004288717A1 (enExample) |
| CA (1) | CA2585876A1 (enExample) |
| DE (1) | DE602004026767D1 (enExample) |
| EA (1) | EA200600920A1 (enExample) |
| WO (1) | WO2005046442A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6896872B2 (en) * | 2001-06-27 | 2005-05-24 | Svetlana A. Dambinova | Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke |
| US20060257943A1 (en) * | 2005-01-25 | 2006-11-16 | Cis Biotech, Inc. | Ischemic biomarkers and their use to predict adverse neurological events from surgery |
| CA2610833A1 (en) * | 2005-06-13 | 2006-12-21 | Cis Biotech, Inc. | Methods for diagnosing and treating cerebrovascular events based on nr2 peptides |
| US8536115B2 (en) | 2006-08-31 | 2013-09-17 | Centre For Addiction And Mental Health | Compositions and methods for modulating AMPA receptor-mediated excitotoxicity |
| WO2013102264A1 (en) * | 2012-01-04 | 2013-07-11 | Centre For Addiction And Mental Health | Compositions and methods for modulating ampa receptor-mediated excitotoxicity |
| US9759722B2 (en) * | 2012-12-17 | 2017-09-12 | Leukodx Ltd. | Systems and methods for determining a chemical state |
| WO2014097286A1 (en) | 2012-12-17 | 2014-06-26 | Leukodx, Ltd. | Systems and methods for determining a chemical state |
| US10610861B2 (en) | 2012-12-17 | 2020-04-07 | Accellix Ltd. | Systems, compositions and methods for detecting a biological condition |
| EP2863231A1 (en) * | 2013-10-17 | 2015-04-22 | Institut D'Investigaciones Biomédiques August Pi i Sunyer | Diagnostic method for detecting a GABA(A) related autoimmune disease and related subject-matter |
| US10194829B2 (en) | 2015-07-07 | 2019-02-05 | Q Bio, Inc. | Fast scanning based on magnetic resonance history |
| US9958521B2 (en) | 2015-07-07 | 2018-05-01 | Q Bio, Inc. | Field-invariant quantitative magnetic-resonance signatures |
| WO2017044919A1 (en) | 2015-09-12 | 2017-03-16 | Q Bio, Inc | Uniform-frequency records with obscured context |
| US10964412B2 (en) | 2015-10-20 | 2021-03-30 | Q Bio, Inc. | Population-based medical rules via anonymous sharing |
| US10222441B2 (en) | 2016-04-03 | 2019-03-05 | Q Bio, Inc. | Tensor field mapping |
| US10359486B2 (en) | 2016-04-03 | 2019-07-23 | Q Bio, Inc. | Rapid determination of a relaxation time |
| US11650195B2 (en) | 2017-02-03 | 2023-05-16 | Q Bio, Inc. | Iterative medical testing of biological samples |
| WO2018144044A1 (en) * | 2017-02-03 | 2018-08-09 | Q Bio, Inc. | lTERATIVE MEDICAL TESTING OF BIOLOGICAL SAMPLES |
| US10936180B2 (en) | 2017-03-16 | 2021-03-02 | Q Bio, Inc. | User interface for medical information |
| US11360166B2 (en) | 2019-02-15 | 2022-06-14 | Q Bio, Inc | Tensor field mapping with magnetostatic constraint |
| US11354586B2 (en) | 2019-02-15 | 2022-06-07 | Q Bio, Inc. | Model parameter determination using a predictive model |
| WO2020241443A1 (ja) | 2019-05-24 | 2020-12-03 | 富士レビオ株式会社 | サイログロブリンの測定方法及び測定試薬 |
| US11614509B2 (en) | 2019-09-27 | 2023-03-28 | Q Bio, Inc. | Maxwell parallel imaging |
| WO2021062154A1 (en) | 2019-09-27 | 2021-04-01 | Q Bio, Inc. | Maxwell parallel imaging |
| US12320880B2 (en) | 2019-09-27 | 2025-06-03 | Q Bio, Inc. | Maxwell parallel imaging |
| EP4036111A4 (en) | 2019-09-27 | 2023-10-25 | Fujirebio Inc. | HEPATITIS B VIRUS CORE ANTIGEN IMMUNOASSAY AND KIT THEREOF |
| CN115335700A (zh) | 2020-03-31 | 2022-11-11 | 富士瑞必欧株式会社 | 血中β淀粉样蛋白的免疫测定方法及用于该方法的试剂盒 |
| CN117616277A (zh) | 2021-08-06 | 2024-02-27 | 株式会社先端生命科学研究所 | 甲状腺球蛋白的免疫检测及用于其的试剂盒 |
| US11614508B1 (en) | 2021-10-25 | 2023-03-28 | Q Bio, Inc. | Sparse representation of measurements |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879289A (en) * | 1988-05-24 | 1989-11-07 | Marion Laboratories, Inc. | Method of ameliorating epileptic seizures |
| CA2071879C (en) * | 1989-10-27 | 2007-05-15 | Stephen F. Heinemann | Glutamate receptor compositions and methods |
| WO1993000586A1 (fr) | 1991-06-26 | 1993-01-07 | Obschestvo S Ogranichennoi Otvetstvennostju 'dies' | Immunoadsorbant utilise dans le diagnostic de l'epilepsie et d'un groupe a risque |
| WO1994006345A2 (en) | 1992-09-11 | 1994-03-31 | Dambinova Svetlana Alexandrovn | Immunosorbent for use in the diagnosis of neuro-psychological disorders, and use thereof |
| RU2112243C1 (ru) | 1995-11-29 | 1998-05-27 | Светлана Александровна Дамбинова | Набор "па-тест" для диагностики неврологических заболеваний |
| US6896872B2 (en) | 2001-06-27 | 2005-05-24 | Svetlana A. Dambinova | Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke |
| US20050233390A1 (en) * | 2003-04-09 | 2005-10-20 | Allen John W | Device including a proteinaceous factor, a recombinant proteinaceous factor, and a nucleotide sequence encoding the proteinaceous factor |
| US20060257943A1 (en) | 2005-01-25 | 2006-11-16 | Cis Biotech, Inc. | Ischemic biomarkers and their use to predict adverse neurological events from surgery |
-
2004
- 2004-11-08 EA EA200600920A patent/EA200600920A1/ru unknown
- 2004-11-08 EP EP04818645A patent/EP1689288B1/en not_active Expired - Lifetime
- 2004-11-08 CN CNA2004800399514A patent/CN1954211A/zh active Pending
- 2004-11-08 JP JP2006539691A patent/JP4838140B2/ja not_active Expired - Fee Related
- 2004-11-08 CA CA002585876A patent/CA2585876A1/en not_active Abandoned
- 2004-11-08 AU AU2004288717A patent/AU2004288717A1/en not_active Abandoned
- 2004-11-08 AT AT04818645T patent/ATE465412T1/de not_active IP Right Cessation
- 2004-11-08 DE DE602004026767T patent/DE602004026767D1/de not_active Expired - Lifetime
- 2004-11-08 WO PCT/US2004/037088 patent/WO2005046442A2/en not_active Ceased
- 2004-11-08 US US10/983,845 patent/US7820398B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005046442A2 (en) | 2005-05-26 |
| US7820398B2 (en) | 2010-10-26 |
| CN1954211A (zh) | 2007-04-25 |
| AU2004288717A2 (en) | 2005-05-26 |
| EA200600920A1 (ru) | 2007-04-27 |
| WO2005046442A3 (en) | 2006-12-07 |
| JP4838140B2 (ja) | 2011-12-14 |
| DE602004026767D1 (de) | 2010-06-02 |
| US20050181466A1 (en) | 2005-08-18 |
| EP1689288A2 (en) | 2006-08-16 |
| AU2004288717A1 (en) | 2005-05-26 |
| JP2007517188A (ja) | 2007-06-28 |
| EP1689288B1 (en) | 2010-04-21 |
| ATE465412T1 (de) | 2010-05-15 |
| EP1689288A4 (en) | 2007-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7820398B2 (en) | Immunosorbent blood tests for assessing paroxysmal cerebral discharges | |
| US20240361342A1 (en) | Lateral flow immunoassay method of simultaneously detecting hemoglobin s, hemoglobin c, and hemoglobin a in newborns, infants, children, and adults | |
| US7622114B2 (en) | Assay methods for immediate diagnosis of cause of stroke | |
| US20110065205A1 (en) | Method for determining prognosis of acute central nervous system disorder | |
| US20100173789A1 (en) | Ischemic biomarkers and their use to predict adverse neurological events from surgery | |
| KR101883515B1 (ko) | 알츠하이머 병의 진단약 및 진단 방법 | |
| WO2021157634A1 (ja) | タウオパチーおよび認知症関連疾患の判定薬および判定方法 | |
| EP2924437B1 (en) | Method for detecting neurological disease accompanied by inflammation and/or demyelination | |
| US8084225B2 (en) | Methods for diagnosing cerebrovascular events based on NR2 peptides | |
| JP6817666B2 (ja) | 精神疾患発症危険状態の診断用バイオマーカー | |
| US20220050118A1 (en) | Method for diagnosing a liver disease | |
| WO2018117913A1 (ru) | Прогнозирование течения и исхода комы и посткоматозных бессознательных состояний (в том числе вегетативных) с помощью гемотестов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |